Close

Islet Sciences chooses NeoStem unit for product manufacturing

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Role of CDMOs in Outsourced Pharmaceutical Manufacturing

The pharmaceutical sector stands at the crossroads of innovation...

Regional Pharma Hubs for Effective Supply Chain Outcomes

It is well to be noted that the pharmaceutical...

Incorporation of Antimicrobial Coatings in Pharmaceuticals

In the very rapidly evolving pharmaceutical spectrum, the safeguarding...

Biopharma Production with AI: A New Era in Manufacturing

A New Era of Biopharma Production with AI The biopharma...

Progenitor Cell Therapy (PCT), a unit of NeoStem’s cell therapy manufacturing, has entered an agreement to provide contract manufacturing and regulatory services related to the development of Islet Sciences’ PTM.

PTM is an injectable suspension of microencapsulated insulin-producing, pancreatic islet cells which are harvested from designated pathogen free pigs.

As per the deal, PCT will perform microencapsulation for parsing beta pancreatic islets for xenotransplantation using piglet pancreata.

Islet Sciences CEO John Steel said NeoStem has agreed to deal whereby PCT will subsidize manufacturing margin related to current services for Islet Sciences – PTM product in exchange for royalties on future sales, exclusive manufacturing rights for both clinical trial and commercial manufacturing and an equity stake in Islet’s parent.

“We recognize that PCT’s track record of developing cell therapies cost efficiently for cell therapy companies makes this a truly compelling opportunity in the industry,” said John Steel, CEO of Islet Sciences,” Steel added.

Islet Sciences is a biotechnology company focused on research, development and commercialization of patented technologies in the field of transplantation therapy for patients with diabetes.

Latest stories

Related stories

Role of CDMOs in Outsourced Pharmaceutical Manufacturing

The pharmaceutical sector stands at the crossroads of innovation...

Regional Pharma Hubs for Effective Supply Chain Outcomes

It is well to be noted that the pharmaceutical...

Incorporation of Antimicrobial Coatings in Pharmaceuticals

In the very rapidly evolving pharmaceutical spectrum, the safeguarding...

Biopharma Production with AI: A New Era in Manufacturing

A New Era of Biopharma Production with AI The biopharma...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back